Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02D (Melanoma Brain Metastasis)
2023-506315-17-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of pembrolizumab, lenvatinib and quavonlimab + pembrolizumab in melanoma and brain metastases (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants who Experience an Adverse Event, Percentage of Participants who Discontinue Study Treatment Due to an Adverse Event and 1 more. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2023-506315-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506315-17-00.